SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
VivoSim Labs received a written notice from Nasdaq on July 20, 2026, indicating failure to meet the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if compliance is not regained within 180 days.
View raw filing on EDGAR →Peraso received a notice from Nasdaq on July 21, 2026, that it failed to maintain the minimum bid price of $1 per share for 30 consecutive business days, triggering a 180-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A). The Company risks delisting if it cannot regain compliance or meet the conditions for a second compliance period.
View raw filing on EDGAR →MDxHealth received a Nasdaq notification on July 20, 2026, that it has failed to maintain the minimum market value of US$35 million required under Nasdaq Listing Rule 5550(b)(2). The company has 180 calendar days (until January 19, 2027) to regain compliance or faces potential delisting. This is a material disclosure of delisting risk under Item 3.01 equivalent, as it directly threatens the company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →Chegg received notice from the NYSE on July 24, 2026, that it failed to maintain the minimum average closing share price of $1.00 over a consecutive 30 trading-day period, violating Section 802.01C of the NYSE Listed Company Manual. The company has a six-month cure period to regain compliance; failure to do so will result in NYSE suspension and delisting procedures.
View raw filing on EDGAR →LiqTech received a deficiency notice from Nasdaq on July 21, 2026, for failing to maintain the $1.00 minimum bid price required under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-calendar-day compliance period (until January 19, 2027) to regain compliance, with potential for a second 180-day period if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.
View raw filing on EDGAR →The filing discloses that Nasdaq has confirmed the Company "has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b)" and that the Company's common stock "will continue to be listed and traded on the Nasdaq Capital Market." This language indicates the Company had previously been at risk of delisting due to non-compliance with these listing rules, and the filing announces resolution of that delisting risk. This is material to investors as it directly affects the continued trading of the company's securities.
View raw filing on EDGAR →NIP Group announced on July 24, 2026 that it has regained compliance with Nasdaq's Minimum Bid Price Requirement (Rule 5450(a)(1)) after receiving a deficiency notice on March 24, 2026 for trading below $1.00 per share for 32 consecutive business days. The company evidenced a closing bid price at or above $1.00 for 10 consecutive business days from July 7–21, 2026, and Nasdaq has closed the deficiency matter. This is a material delisting-risk disclosure because it documents resolution of a listing-compliance violation that, if unresolved, would have resulted in delisting.
View raw filing on EDGAR →Arrive AI received a notification letter from Nasdaq on July 21, 2026 (Item 3.01) stating the company failed to maintain the minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000 for 32 consecutive business days. The company has 180 calendar days until January 19, 2027 to regain compliance or face delisting. This is a clear delisting-risk disclosure under Item 3.01 of Form 8-K.
View raw filing on EDGAR →Fusemachines received a notification letter from Nasdaq on July 24, 2026 indicating non-compliance with the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $15,000,000 for the Nasdaq Global Market. The company has 180 calendar days until January 20, 2027 to regain compliance, or face potential delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →GoPro received a notice from Nasdaq on July 21, 2026, that it failed to comply with Listing Rule 5450(a)(1) because the minimum bid price of its Class A Common Stock has been below $1.00 per share for thirty consecutive business days. The company has 180 calendar days to regain compliance by achieving a minimum bid price of $1.00 or above for ten consecutive business days. This is a classic delisting-risk disclosure under Item 3.01, signaling potential loss of listing status if the company cannot meet the price threshold within the grace period.
View raw filing on EDGAR →The press release discloses that Cycurion received a delisting determination from Nasdaq on July 10, 2026, for failure to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(1). The Company has requested a hearing before the Nasdaq Hearings Panel scheduled for August 2026 to appeal the delisting determination. This is a material disclosure of delisting risk that directly threatens the Company's continued listing on Nasdaq.
View raw filing on EDGAR →Quantum-Si received written notice from Nasdaq on July 23, 2026, that its Class A common stock has fallen below the $1.00 minimum bid price requirement for 30 consecutive business days, triggering a delisting notice under Nasdaq Listing Rule 5450(a)(1). The company has been granted an initial 180-day compliance period (until January 19, 2027) to regain compliance, with the possibility of an additional 180-day period if it transfers to the Nasdaq Capital Market. This is a material delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →D-Wave announces a "voluntary transfer of its common stock listing" from its prior exchange to Nasdaq, effective July 27, 2026. While framed positively as a "listing debut" and strategic move to "the leading exchange for technology companies," this constitutes a material change in listing venue. The disclosure of a transfer of listing falls within Item 3.01 (Delisting or Transfer of Listing) territory, though the company characterizes it as a positive development rather than a delisting risk per se. The materiality is clear—a change in primary listing exchange affects trading, visibility, and investor access.
View raw filing on EDGAR →The filing explicitly discloses a notice to Nasdaq of non-compliance with continued listing rules (Nasdaq Listing Rule 5605(c)(2)) regarding audit committee independence requirements. Although the company has remediated the violation by Mr. Jenkins' resignation from the Audit Committee, the initial notice of failure to satisfy a continued listing standard is the material event triggering Item 3.01 disclosure and represents delisting risk.
View raw filing on EDGAR →Aprea Therapeutics received notification from Nasdaq on July 23, 2026, that while it has not yet regained compliance with the $1.00 minimum bid price requirement, it has been granted an additional 180-day compliance period until January 19, 2027. The disclosure explicitly states that if compliance cannot be demonstrated by that date, Nasdaq will provide written notification that the Common Stock will be delisted. This is a classic delisting-risk disclosure under Item 3.01, indicating the company faces imminent delisting if it fails to meet the minimum bid price threshold.
View raw filing on EDGAR →Fly-E Group received a delinquency notification from Nasdaq on July 21, 2026, for non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-K. The Notice explicitly states that if the Company fails to regain compliance, "the Company's securities will be subject to delisting from Nasdaq." This is a classic delisting-risk disclosure under Item 3.01, even though the Company filed the 10-K on July 23, 2026, eliminating the immediate compliance issue.
View raw filing on EDGAR →The filing discloses that Nasdaq issued a deficiency letter on April 29, 2026, citing the Company's failure to maintain the minimum $2,500,000 stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) as of December 31, 2025. Although the Company states it has regained compliance through recent transactions (a $1.7M equity issuance and $1.485M in recognized revenue), Nasdaq explicitly warned that if compliance is not evidenced at the next periodic report, the Company "may be subject to delisting." This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →MaxsMaking received a Staff Delisting Determination from Nasdaq dated July 17, 2026, stating that Nasdaq has determined to delist the Company's securities pursuant to Nasdaq Listing Rule IM-5101-4. The delisting follows an SEC temporary trading suspension on November 17, 2025, and a Nasdaq trading halt on December 2, 2025. This is a material event that directly threatens the registrant's continued listing and market access.
View raw filing on EDGAR →The disclosure announces that SPAR Group's Common Stock has been delisted from Nasdaq and will begin trading on the OTCQB effective July 23, 2026. The Item 8.01 filing states "the Company received a determination letter from Nasdaq notifying the Company that its Common Stock would be delisted from Nasdaq and that trading would be suspended absent a successful appeal." This is a completed delisting event—the company's listing status has changed from a major national exchange to an over-the-counter market, which materially affects liquidity, visibility, and investor access to the stock.
View raw filing on EDGAR →Viomi received a written notification from Nasdaq dated July 22, 2026, indicating that its ADSs failed to meet the minimum bid price requirement of US$1.00 per share for 30 consecutive business days. The company has been granted a 180-day compliance period (until January 19, 2027) to regain compliance. This is a classic delisting-risk disclosure under Nasdaq Listing Rule 5450(a)(1), materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →Real Messenger received a Nasdaq notification letter dated July 22, 2026, stating that the Company failed to maintain the minimum closing bid price of $1 per share for 30 consecutive business days, triggering Nasdaq Listing Rule 5550(a)(2) deficiency. While the letter does not result in immediate delisting, the Company has 180 calendar days (until January 19, 2027) to regain compliance or face potential delisting. The disclosure explicitly states that "if the Company does not regain compliance by January 19, 2027... Nasdaq will provide notice that its securities will be subject to delisting," and acknowledges "there can be no assurance that the Company will be able to timely regain or maintain compliance." This is a material delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →InspireMD received a notice from Nasdaq on July 17, 2026 that it failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The company has been given a 180-day compliance period until January 13, 2027 to regain compliance, with the explicit warning that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →Almonty announces its voluntary delisting from the Australian Securities Exchange (ASX), effective September 1, 2026. The company cites low and declining trading volumes (CDIs representing only 0.80% of issued shares as of July 14, 2026) and the burden of maintaining ASX listing compliance. This is a material disclosure of delisting that directly affects shareholders' ability to trade on ASX and requires conversion or sale of CDIs through specified facilities.
View raw filing on EDGAR →Nuvve received a "Delist Determination" from Nasdaq's Hearings Panel on July 22, 2026, ordering delisting of its common stock from The Nasdaq Capital Market effective July 24, 2026, due to failure to comply with three listing rules: the periodic reporting requirement (Form 10-Q filing), the $1.00 bid price rule, and the $2.5 million stockholders' equity requirement. The company's stock will be suspended and transferred to the OTC Pink Limited Information Tier. This is a definitive delisting notice, not merely a risk or warning, making it a material event that fundamentally affects the registrant's market access and investor base.
View raw filing on EDGAR →The 6-K discloses that NetClass Technology received a Nasdaq deficiency notice on January 27, 2026 for failing to meet the minimum bid price requirement (below $1.00 for 30 consecutive business days), was given a 180-day compliance period until July 27, 2026, and subsequently regained compliance on July 21, 2026 following a 50-for-1 reverse stock split effective July 6, 2026. This is a material delisting risk event that was resolved through the reverse split, with Nasdaq confirming restoration of compliance on July 21, 2026.
View raw filing on EDGAR →The filing discloses that GDEV Inc.'s public warrants (GDEVW) will expire on August 26, 2026, and upon expiration "will cease to trade and will be delisted from the Nasdaq Global Market." This is a notice of delisting of a security, which falls squarely within the delisting_risk category. While the warrants themselves are "currently out of the money," the material fact is the announced delisting of a publicly traded security from Nasdaq.
View raw filing on EDGAR →Following completion of the merger, NSA notified the NYSE of delisting. The NYSE suspended trading and filed Form 25 notifications removing NSA Common Shares, Series A Preferred Shares, and Series B Preferred Shares from listing, with NSA intending to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →Northfield Common Stock was delisted from NASDAQ effective July 20, 2026, following completion of the merger with Columbia Financial. Columbia Financial intends to file Form 15 to deregister the stock and suspend reporting obligations.
View raw filing on EDGAR →Purple Innovation received a Nasdaq Panel decision on July 20, 2026 granting continued listing subject to strict conditions: the company must demonstrate a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days by July 31, 2026. The filing explicitly discloses delisting risk, noting "there can be no assurance that the Company will regain compliance" and that failure to do so would result in delisting from Nasdaq. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →SunPower received written notice from Nasdaq on July 21, 2026, that it failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5450(a)(1). The company has 180 calendar days to regain compliance, with delisting as a consequence if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public listing status.
View raw filing on EDGAR →The filing discloses a Nasdaq delisting notice under Item 3.01, indicating the Company failed to maintain the $1.00 minimum bid price requirement for 30 consecutive business days. While Item 1.01 addresses a standstill agreement with a convertible preferred investor, the material event is the delisting risk: the Company has until January 13, 2027 to regain compliance or face delisting. This is a terminal threat to the registrant's continued public trading status.
View raw filing on EDGAR →Empro Group received a Staff Delisting Determination from Nasdaq on July 16, 2026, notifying the Company that Nasdaq has determined to delist its securities pursuant to Listing Rule IM-5101-4, citing both discretionary authority and the Company's delay in filing Form 20-F. The delisting is triggered by an SEC trading suspension order issued October 8, 2025, due to potential market manipulation. Trading suspension is scheduled for July 27, 2026, unless the Company appeals by July 23, 2026. This is a material delisting event that directly threatens the Company's continued listing and market access.
View raw filing on EDGAR →MicroVision announced a 1-for-15 reverse stock split explicitly "intended to increase the per-share trading price of MicroVision's common stock to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market." The press release states the reverse split "supports our continued Nasdaq listing," indicating the company faced delisting risk due to non-compliance with Nasdaq's minimum bid price requirement. This is a material disclosure of a listing compliance issue and the remedial action taken.
View raw filing on EDGAR →The filing discloses a 1-for-40 reverse stock split explicitly undertaken to "enable the Company to manage continued compliance with The Nasdaq Capital Market Listing Rule 5550(a)(2)" — the minimum bid price rule. The press release states the split is "intended to increase the closing bid price of the Common Stock above $1.00 per share" to maintain Nasdaq listing compliance. This is a direct response to delisting risk triggered by failure to meet the minimum bid price requirement.
View raw filing on EDGAR →The Company received notification from OTC Markets Group that its common stock has been moved to the OTC Expert Market on an unsolicited quotes only basis. This represents a material downgrade in listing status and a significant delisting risk event, as movement to the OTC Expert Market typically indicates failure to meet continued listing standards and substantially reduces liquidity and investor access to the stock.
View raw filing on EDGAR →SOLAI Limited received a written notice from the NYSE on July 16, 2026, indicating that NYSE Regulation has determined to commence delisting proceedings for the Company's ADSs due to failure to maintain the minimum average global market capitalization of US$15,000,000 over a consecutive 30 trading day period. Trading was suspended on July 16, 2026, and the Company expects the ADSs to transition to OTC Markets. This is a clear delisting notice triggering the formal delisting process under NYSE Listed Company Manual Section 802.01B.
View raw filing on EDGAR →Cypherpunk Technologies received a Nasdaq deficiency notice on July 20, 2026, for failing to maintain the minimum $1.00 closing bid price required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The company has 180 days until January 19, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the registrant's continued listing status and investor confidence.
View raw filing on EDGAR →KORE notified the NYSE of the completion of the merger and requested suspension of trading and delisting of its common stock prior to market open on July 21, 2026. The company intends to file Form 15 to terminate its registration under Section 12(g) and suspend reporting obligations.
View raw filing on EDGAR →On July 17, 2026, Nuburu received a delisting notice from NYSE American because its common stock traded below $0.10, violating Section 1003(f)(v) of the NYSE American Company Guide. The company intends to appeal and implement a reverse stock split to regain compliance.
View raw filing on EDGAR →The 6-K discloses a change in ticker symbol from YOOV to CIGL, effective July 21, 2026, on the Nasdaq Capital Market. While a ticker change alone is not necessarily a delisting event, it often signals a transfer of listing or a change in market tier (e.g., from Nasdaq Global Market to Nasdaq Capital Market, or vice versa). The disclosure of a "new ticker symbol" and the specific effective date suggest a material change in the registrant's listing status that would affect investor identification and trading of the security.
View raw filing on EDGAR →The filing discloses that XTL Biopharmaceuticals has regained compliance with Nasdaq listing rules after a prior delisting threat, but remains subject to a one-year mandatory panel monitor with heightened consequences: any future breach of the Equity Rule will result in immediate delisting without cure rights. This is material because it signals ongoing listing vulnerability and constrains the company's operational flexibility during the monitoring period.
View raw filing on EDGAR →Nasdaq Listing Qualifications Staff issued a determination letter on July 16, 2026 to delist the Company's common stock and warrants based on violations of Nasdaq Listing Rules 5205(e) and 5250(a)(1) related to disclosures regarding China Securities Regulatory Commission review status. The Company intends to appeal by July 23, 2026, but faces immediate delisting if the Panel reaches a unanimous decision against it.
View raw filing on EDGAR →Picard Medical implemented a 1-for-50 reverse stock split to support continued compliance with NYSE American continued listing standards. The reverse split was undertaken to address delisting risk and maintain the company's exchange listing.
View raw filing on EDGAR →CN Energy Group received a written notification from Nasdaq dated July 15, 2026, stating it is no longer in compliance with Nasdaq Listing Rule 5550(a)(2) due to a closing bid price below $1.00 per share for 30 consecutive business days. Although the Company has a 180-day grace period (until January 12, 2027) to regain compliance, this is a material delisting risk disclosure that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →This exhibit announces CLINUVEL's commencement of trading on Nasdaq under ticker CUVL, with its existing over-the-counter ADR (CLVLY) upgrading from Level I to Level II. While the announcement describes a positive listing development, the risk statement explicitly notes "No final decision has been made" and "There is no guarantee that the uplisting will proceed." However, the primary substance is a successful listing event rather than a delisting risk, making this classification uncertain.
View raw filing on EDGAR →The exhibit discloses Above Food's engagement of counsel to appeal a Nasdaq delisting determination before the Nasdaq Listing and Hearing Review Council. The company explicitly states it "has requested review of Nasdaq's prior delisting determination" and references an outstanding Form 20-F filing obligation under Listing Rule 5250(c)(1). This is a material delisting-risk disclosure under Item 3.01 equivalent, as the company faces potential loss of listing due to non-compliance with filing requirements.
View raw filing on EDGAR →The Nasdaq Hearings Panel issued a final delisting determination denying Sangamo's request to continue listing on The Nasdaq Capital Market due to failure to meet the minimum bid price requirement. The company's stock has been suspended from Nasdaq and is now trading on the OTCID Basic Market, with Nasdaq expected to file a Form 25 to delist and deregister the common stock.
View raw filing on EDGAR →The filing discloses that Tenon Medical regained compliance with Nasdaq's Stockholders' Equity Rule (minimum $2.5 million) following a $4.2 million public offering on July 1, 2026. However, the company explicitly warns that "if the Company fails to evidence compliance upon filing its Quarterly Report on Form 10-Q for the period ending September 30, 2026, the Company may be subject to delisting." This is a material delisting risk disclosure under Item 8.01, as the company faces potential delisting if it cannot maintain the minimum equity threshold in its next quarterly report.
View raw filing on EDGAR →The filing discloses a definitive delisting determination by the Nasdaq Hearings Panel on July 17, 2026, with trading suspension effective July 21, 2026, due to failure to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company's common stock will transfer from Nasdaq to the OTC Markets, materially reducing liquidity and trading price. This is a terminal delisting event, not merely a risk or notice of non-compliance.
View raw filing on EDGAR →TEN Holdings received a deficiency letter from Nasdaq for failing to maintain the minimum $2,500,000 stockholders' equity required under Listing Rule 5550(b)(1), and while the company believes it has regained compliance through a $6.6 million registered direct offering, Nasdaq will continue monitoring and may subject the company to delisting if it fails to evidence compliance at its next periodic report. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →